Posted in | News | Optics and Photonics

ODIS Wins Contract for Optical Code Division Multiple Access Technology Development

Designer of communication transceivers, ODIS has been awarded a development contract by the Navy Air Warfare Center, including a $150,000 Phase I award. The Navy conducted research on ODIS, and then chose the company’s PlanarOptoElectric Technology (POET) platform, to build an optical code division multiple access (OCDMA) technology. The technology will be used for developing future avionic systems.

CDMA technology is utilized in the wireless sector to allocate channel safely to a wide user base. ODIS was awarded the contract along with NAVAIR, for developing OCDMA integrated OE circuit approaches for applications in Navy Avionics platforms. The OCDMA technology provides improved security, which will be installed at various levels in the optical avionics processor networks of the Department of Defense. The levels of security are attained because of tough encryption techniques provided by Pseudo-random Noise sequencing.

The POET is the latest semiconductor fabrication process of ODIS. It features a patented Group III-V materials system, which supports performing monolithic fabrication of ICs featuring passive and active optical elements. A cost-effective integration of numerous optical units along with high-speed, dense analog elements, and low-power digital elements are made possible in the monolithic ICs. The POET platform enables ODIS to modify the landscape for diverse applications by providing units with significantly low cost, and improved reliability, density and speed.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.